Core Scientific (CORZR) Equity Average (2021 - 2026)

Core Scientific's Equity Average history runs 6 years deep, the most recent figure standing at -$1.1 billion for Q1 2026.

• In Q1 2026, Equity Average fell 81.2% year-over-year to -$1.1 billion; the TTM figure through Mar 2026 stood at -$1.1 billion (down 81.2% YoY), while the FY2025 annual figure was -$952.9 million, down 23.75% from the prior year.
• Equity Average came in at -$1.1 billion for Q1 2026 at Core Scientific, down from -$1.1 billion in the prior quarter.
• In the past five years, Equity Average ranged from a high of $1.2 billion in Q1 2022 to a low of -$1.2 billion in Q3 2025.
• A 5-year average of -$445.1 million and a median of -$507.8 million in 2023 frame the typical range for Equity Average.
• Across the five-year window, Equity Average soared 1224.13% in 2022 and plunged 265.72% in 2023, its largest moves.
• Core Scientific's Equity Average stood at -$168.2 million in 2022, then sank by 202.0% to -$507.8 million in 2023, then slumped by 74.24% to -$884.9 million in 2024, then slipped by 25.18% to -$1.1 billion in 2025, then decreased by 2.39% to -$1.1 billion in 2026.
• According to Business Quant data, Equity Average over the past three periods registered -$1.1 billion, -$1.1 billion, and -$1.2 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison